Searching News Database: insomnia
HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
HSMN NewsFeed - 27 Mar 2019
FDA Clears the Cervella Cranial Electrotherapy Stimulator for Treatment of Anxiety, Insomnia, and Depression
FDA Clears the Cervella Cranial Electrotherapy Stimulator for Treatment of Anxiety, Insomnia, and Depression
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
HSMN NewsFeed - 6 Oct 2016
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 24 Feb 2016
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
HSMN NewsFeed - 19 Mar 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
HSMN NewsFeed - 11 Feb 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
HSMN NewsFeed - 5 Jul 2013
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
HSMN NewsFeed - 8 May 2013
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
HSMN NewsFeed - 5 Feb 2013
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
HSMN NewsFeed - 11 Dec 2012
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.
HSMN NewsFeed - 24 Sep 2012
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development
HSMN NewsFeed - 10 Sep 2012
Merck Announces New Phase III Data for Suvorexant, an Investigational Insomnia Medicine
Merck Announces New Phase III Data for Suvorexant, an Investigational Insomnia Medicine
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 19 Jul 2012
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Zydus
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Zydus
HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 5 Apr 2012
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 20 Jan 2012
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 1 Feb 2011
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 18 Jan 2011
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV (acetaminophen) Injection
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV (acetaminophen) Injection
HSMN NewsFeed - 3 Nov 2010
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
HSMN NewsFeed - 25 Aug 2010
Somaxon Pharmaceuticals Announces Silenor(R) Co-Promotion Agreement with Procter & Gamble
Somaxon Pharmaceuticals Announces Silenor(R) Co-Promotion Agreement with Procter & Gamble
HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
HSMN NewsFeed - 7 May 2010
Meda Acquires Exclusive Rights to flupirtine for fibromyalgia, a Potential USD Billion Indication
Meda Acquires Exclusive Rights to flupirtine for fibromyalgia, a Potential USD Billion Indication
HSMN NewsFeed - 12 Apr 2010
Somaxon Pharmaceuticals Appoints Chief Financial Officer and Announces Senior Leadership Promotions
Somaxon Pharmaceuticals Appoints Chief Financial Officer and Announces Senior Leadership Promotions
HSMN NewsFeed - 23 Mar 2010
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
HSMN NewsFeed - 18 Mar 2010
Somaxon Announces FDA Approval of Silenor(R) (doxepin) for the Treatment of Insomnia
Somaxon Announces FDA Approval of Silenor(R) (doxepin) for the Treatment of Insomnia
HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
HSMN NewsFeed - 22 Feb 2010
Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review
Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 17 Dec 2009
Sepracor Granted Patent Term Extension for LUNESTA(R) and Provides Update on LUNESTA Pediatric Studies
Sepracor Granted Patent Term Extension for LUNESTA(R) and Provides Update on LUNESTA Pediatric Studies
HSMN NewsFeed - 10 Dec 2009
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
HSMN NewsFeed - 29 Oct 2009
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
HSMN NewsFeed - 13 May 2009
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
HSMN NewsFeed - 11 May 2009
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
HSMN NewsFeed - 5 May 2009
Takeda Global Research & Development Center, Inc., U.S. Names Dr. Azmi Nabulsi President
Takeda Global Research & Development Center, Inc., U.S. Names Dr. Azmi Nabulsi President
HSMN NewsFeed - 16 Mar 2009
Orexo's Edluar (Sublinox) Receives FDA Approval for the Treatment of Insomnia
Orexo's Edluar (Sublinox) Receives FDA Approval for the Treatment of Insomnia
HSMN NewsFeed - 2 Mar 2009
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
HSMN NewsFeed - 23 Feb 2009
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
HSMN NewsFeed - 31 Jan 2009
FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
HSMN NewsFeed - 29 Jan 2009
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
HSMN NewsFeed - 22 Oct 2008
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
HSMN NewsFeed - 5 Sep 2008
Questcor Strengthens Management Team's Manufacturing and Commercial Operations Capabilities
Questcor Strengthens Management Team's Manufacturing and Commercial Operations Capabilities
HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 18 Aug 2008
Somaxon Pharmaceuticals Announces the Appointment of Senior Commercial Leadership
Somaxon Pharmaceuticals Announces the Appointment of Senior Commercial Leadership
HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
HSMN NewsFeed - 7 Aug 2008
Somaxon Pharmaceuticals Appoints Richard W. Pascoe as President and Chief Executive Officer
Somaxon Pharmaceuticals Appoints Richard W. Pascoe as President and Chief Executive Officer
HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
HSMN NewsFeed - 29 May 2008
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
HSMN NewsFeed - 23 May 2008
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
HSMN NewsFeed - 19 May 2008
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
HSMN NewsFeed - 27 Feb 2008
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
HSMN NewsFeed - 4 Feb 2008
Neurogen Corporation Announces Appointment of Stephen R. Davis as President & CEO
Neurogen Corporation Announces Appointment of Stephen R. Davis as President & CEO
HSMN NewsFeed - 31 Jan 2008
Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
HSMN NewsFeed - 17 Jan 2008
ReachMD Appoints Pharmaceutical Veteran as Executive Vice President of Sales and Business Development
ReachMD Appoints Pharmaceutical Veteran as Executive Vice President of Sales and Business Development
HSMN NewsFeed - 14 Jan 2008
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
HSMN NewsFeed - 10 Jan 2008
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
HSMN NewsFeed - 8 Dec 2007
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
HSMN NewsFeed - 6 Dec 2007
Somaxon Pharmaceuticals Names David F. Hale Executive Chairman and Interim Chief Executive Officer
Somaxon Pharmaceuticals Names David F. Hale Executive Chairman and Interim Chief Executive Officer
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
HSMN NewsFeed - 14 Nov 2007
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
HSMN NewsFeed - 25 Sep 2007
Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development
Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development
HSMN NewsFeed - 14 Sep 2007
Neurogen Corporation Announces Appointment of Stephen R. Davis as President
Neurogen Corporation Announces Appointment of Stephen R. Davis as President
HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
HSMN NewsFeed - 30 Aug 2007
Neurogen Corporation Announces Appointment of George D. Maynard to Vice President
Neurogen Corporation Announces Appointment of George D. Maynard to Vice President
HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
HSMN NewsFeed - 2 Jul 2007
Tamiflu(R) 30 mg and 45 mg Capsules Approved by U.S. Food and Drug Administration
Tamiflu(R) 30 mg and 45 mg Capsules Approved by U.S. Food and Drug Administration
HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
HSMN NewsFeed - 22 Jun 2007
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
HSMN NewsFeed - 13 Jun 2007
Dale M. Edgar, Ph.D., to Join Lilly; Will Head Lilly Research Lab's Discovery Sleep Research Efforts
Dale M. Edgar, Ph.D., to Join Lilly; Will Head Lilly Research Lab's Discovery Sleep Research Efforts
HSMN NewsFeed - 12 Jun 2007
Neurocrine Announces Resubmission of New Drug Application for Indiplon Capsules
Neurocrine Announces Resubmission of New Drug Application for Indiplon Capsules
HSMN NewsFeed - 7 Jun 2007
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
HSMN NewsFeed - 15 May 2007
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
HSMN NewsFeed - 14 May 2007
Questcor Receives FDA Action Letter for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
Questcor Receives FDA Action Letter for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
HSMN NewsFeed - 14 May 2007
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 9 May 2007
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program
HSMN NewsFeed - 7 May 2007
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
HSMN NewsFeed - 2 May 2007
Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity
Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 26 Apr 2007
Ranbaxy Receives Final Approval to Manufacture and Market Zolpidem Tablets for Insomnia
Ranbaxy Receives Final Approval to Manufacture and Market Zolpidem Tablets for Insomnia
HSMN NewsFeed - 25 Apr 2007
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 23 Apr 2007
Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval to Market Generic Ambien(R)
Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval to Market Generic Ambien(R)
HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
HSMN NewsFeed - 20 Feb 2007
Neurocrine Biosciences Announces the Resignation of Adrian Adams From the Board of Directors
Neurocrine Biosciences Announces the Resignation of Adrian Adams From the Board of Directors
HSMN NewsFeed - 8 Feb 2007
Lundbeck USA Signs Lease Agreement to Establish U.S. Headquarters in King of Prussia, Pennsylvania
Lundbeck USA Signs Lease Agreement to Establish U.S. Headquarters in King of Prussia, Pennsylvania
HSMN NewsFeed - 29 Jan 2007
Somaxon Pharmaceuticals Names Robert Jones Vice President, Human Resources
Somaxon Pharmaceuticals Names Robert Jones Vice President, Human Resources
HSMN NewsFeed - 22 Jan 2007
Neurocrine Announces Plans to Resubmit NDA for Indiplon Capsules in Q2 2007
Neurocrine Announces Plans to Resubmit NDA for Indiplon Capsules in Q2 2007
HSMN NewsFeed - 19 Jan 2007
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
HSMN NewsFeed - 9 Jan 2007
Takeda Pharmaceuticals North America Names Vice President of Human Resources and Administration
Takeda Pharmaceuticals North America Names Vice President of Human Resources and Administration
HSMN NewsFeed - 5 Jan 2007
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 4 Dec 2006
LUNESTA(R) Perimenopause-Menopause Study Published in Journal of Obstetrics and Gynecology
LUNESTA(R) Perimenopause-Menopause Study Published in Journal of Obstetrics and Gynecology
HSMN NewsFeed - 28 Nov 2006
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
HSMN NewsFeed - 13 Nov 2006
Somaxon Pharmaceuticals Names Brian Dorsey Vice President of Manufacturing and Program Management
Somaxon Pharmaceuticals Names Brian Dorsey Vice President of Manufacturing and Program Management
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
HSMN NewsFeed - 13 Oct 2006
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
HSMN NewsFeed - 13 Oct 2006
Merck & Co., Inc. and Lundbeck Announce Update in Submission Plans for U.S. Approval of Gaboxadol
Merck & Co., Inc. and Lundbeck Announce Update in Submission Plans for U.S. Approval of Gaboxadol
HSMN NewsFeed - 12 Oct 2006
Newly Published Data Show Efficacy and Safety of LUNESTA(R) in Elderly Patients with Insomnia
Newly Published Data Show Efficacy and Safety of LUNESTA(R) in Elderly Patients with Insomnia
HSMN NewsFeed - 6 Oct 2006
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
HSMN NewsFeed - 12 Sep 2006
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
HSMN NewsFeed - 19 Jul 2006
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program for the Treatment of Insomnia
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program for the Treatment of Insomnia
HSMN NewsFeed - 18 Jul 2006
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
HSMN NewsFeed - 15 May 2006
Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of Legal Affairs
Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of Legal Affairs
Additional items found! 371
Members Archive contains
371 additional stories matching:
insomnia
(Password required)
insomnia
(Password required)